Adopting Site Quality Management to Optimize Risk-Based Monitoring
As it is now well documented, clinical R&D organizations have been actively embarking on a paradigm shift in their approach to ensuring quality in the conduct of clinical trials. In particular, a more targeted, risk-based approach to site monitoring and data cleaning is being actively pursued by organizations both large and small. The primary goals of this new paradigm include significant improvements in resource efficiency associated with clinical R&D, increased quality in trial conduct and corresponding data, and the maintenance or even reduction of clinical trial timelines.
While the interest in this paradigm has increased steadily in recent years, progress had been significantly impeded by a variety of factors. However, now that electronic data capture (EDC) technology is near ubiquitous and the FDA has delivered guidance in favor of centralized monitoring, sponsors are now more interested than ever in trying to implement a risk-based monitoring strategy.
This white paper will help you understand the challenges faced when implementing risk-based monitoring and how developing a site quality management program, especially one leveraging real-time site quality analytics, can simplify the adoption and increase your chances for success.
Have Your Say
Rate this feature and give us your feedback in the comments section below
About Medidata Solutions Worldwide
Medidata Solutions is a leading global provider of SaaS clinical development solutions that enhance the efficiency of customers’ clinical trials. Medidata’s advanced solutions lower the total cost of clinical development by optimising clinical trials from concept to conclusion: from study and protocol design, trial planning and budgeting, site negotiation, clinical portal, trial management, randomisation and trial supply management, clinical data capture and management, safety events capture, medical coding to business analytics. Our diverse life science customer base spans biopharmaceutical companies, medical device and diagnostic companies, academic and government institutions, CROs and other research organisations, and includes more than 20 of the top 25 global pharmaceutical companies as well as organisations of all sizes developing life-enhancing medical treatments and diagnostics.
mdsol.com | email@example.com | +44 (0) 1895 275697
To receive the white paper on this topic please submit your information in the form below.
By entering in your information and submitting the form, you give the sponsor permission to contact you regarding their product.